Skip to content

Clinical trials

Colonic Neoplasms trials in Spain with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Colonic Neoplasms Phase: Not applicable Country / region: Spain Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20071
20111
20151
20171
20181
20194
20203
20212
20223
20233
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Unknown status5
Recruiting4
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Corporacion Parc Tauli3
Universidad Complutense de Madrid3
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud2
Hospital de Granollers2
ADVANCED MARKER DISCOVERY S.L.1
Fondazione Poliambulanza Istituto Ospedaliero1
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León1
Hospital Clinico Universitario de Santiago1
Hospital Provincial de Castellon1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Colonic Neoplasms25
Breast Neoplasms4
Neoplasms4
Colorectal Neoplasms2
Postoperative Complications2
Rectal Neoplasms2
Surgical Wound Infection2
Adenoma1
Anxiety Disorders1
Body Dysmorphic Disorders1

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.